EU drug regulator recommends clearing vaccine for monkeypox

LONDON (AP) — The European Medicines Agency said Friday that the smallpox vaccine made by Bavarian Nordic should also be authorised against monkeypox, as the outbreak of the once-rare disease continues to sicken people across the continent.

The European Union drug regulator said its recommendation was based on animal studies that suggest the vaccine protects non-human primates from monkeypox.

It is up to the EU's executive arm, the European Commission, to formally approve the vaccine based on the EMA's recommendation.

“To confirm the effectiveness of the vaccine against monkeypox, the company will collect data from an observational study that will be carried out during the ongoing monkeypox outbreak in Europe,” the EMA said.

It added that the vaccine's safety profile was “favourable” and the benefits of its use during the ongoing monkeypox outbreak outweighed the risks, noting mostly mild to moderate side effects.

The vaccine, known as Imvanex in Europe but sold as Jynneos in the United States, was already cleared for use against monkeypox by American regulators.

Of the more than 15,000 monkeypox cases reported worldwide, nearly 70% are in Europe, with more than 30 countries across the continent affected.

Doses of the Bavarian Nordic vaccine are extremely limited. Most of the world's supply has already been bought by countries and regions including Britain, Canada, the EU and the United States.

None have gone to Africa, where a more severe version of monkeypox has killed dozens of people. No monkeypox deaths have been reported in rich countries.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.